This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
4 - 6 June, 2024
Excel London Platinum Suite

Michael Dyson, Ph.D.
Vice President, Antibody Discovery and Engineering at Ichnos Sciences


Michael Dyson is Vice President, Antibody Discovery and Engineering. Previously he was Senior Director at Ichnos Sciences responsible for the antibody discovery, optimization, screening, and characterization leading to the development of novel bi- or tri- specific immune engager therapeutics for cancer immunotherapy. He was Chief Technology Officer and co-founder at IONTAS Ltd., a therapeutic antibody discovery company where he either directly project managed or oversaw 56 antibody discovery and development projects partnered with 30 companies including 5 top 20 Pharmas. This included the development of 8 biologics (antibody or bi-specific format) to commence human clinical trials or approaching IND filing to treat auto-immune disease or cancer. Mike was previously Head of Protein Engineering at Acambis plc (acquired by Sanofi) and Project Leader at the Wellcome Trust Sanger Institute. He holds a PhD in organic synthetic chemistry from the University of Birmingham and post-docs at MIT and the Universities of Edinburgh and Cambridge. He has published 40 papers and book chapters (cited over 1800 times) and is inventor on 16 patent and patent applications mainly focused on novel antibody therapeutics.

Agenda Sessions

  • Structural Insights into the Mechanism of Action of ISB 1442, A First-in-class Bispecific Biparatopic Anti-CD38 x CD47 Innate Cell Modulator